AKEEM BOROM: Open Payments
NPI 1316679822 · ORANGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,733 in 163 payments from 19 companies in 2025. Trend: 2023 $0 · 2024 $3,166 · 2025 $3,733
Food & beverage: $3,733
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 14 | $584 |
| Neurocrine BioSciences, Inc. | 17 | $556 |
| ABBVIE INC. | 19 | $447 |
| E.R. Squibb & Sons, L.L.C. | 16 | $351 |
| Alkermes, Inc. | 11 | $274 |
| Otsuka America Pharmaceutical, Inc. | 12 | $271 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $231 |
| Teva Pharmaceuticals USA, Inc. | 13 | $231 |
| Lundbeck LLC | 14 | $207 |
| Vanda Pharmaceuticals Inc. | 11 | $201 |
Products named: INGREZZA, VRAYLAR, SPRAVATO, REXULTI, COBENFY, ARISTADA, CAPLYTA, FANAPT.
Industry payments across CA — which companies pay providers there.
